NASDAQ:FBRX Forte Biosciences Q3 2025 Earnings Report $12.08 +0.12 (+1.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$11.80 -0.28 (-2.31%) As of 10/17/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Forte Biosciences EPS ResultsActual EPSN/AConsensus EPS -$1.04Beat/MissN/AOne Year Ago EPSN/AForte Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AForte Biosciences Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateTuesday, November 11, 2025Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Forte Biosciences Earnings HeadlinesForte Biosciences (FBRX) Price Target Increased by 16.98% to 53.30October 1, 2025 | msn.comForte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease SymposiumSeptember 15, 2025 | finance.yahoo.comBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market. | Altimetry (Ad)We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash WiselySeptember 11, 2025 | finance.yahoo.comForte Biosciences Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comGuggenheim Initiates Coverage of Forte Biosciences (FBRX) with Buy RecommendationAugust 19, 2025 | msn.comSee More Forte Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email. Email Address About Forte BiosciencesForte Biosciences (NASDAQ:FBRX) is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions. The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis. FB-401 has shown promise in early studies for reducing inflammation and improving barrier function, and is currently being evaluated in Phase 2 clinical trials. In addition to atopic dermatitis, Forte is exploring pipeline opportunities in rare genetic skin conditions such as epidermolysis bullosa, where reinforcing the skin’s protective barrier is a critical unmet need. Forte Biosciences conducts clinical research across North America and Europe, collaborating with academic institutions and patient advocacy groups to accelerate development timelines. The company’s management team comprises professionals with extensive experience in biotechnology R&D, regulatory affairs, and commercial strategy, positioning Forte to translate scientific discoveries into potential therapeutic options for patients with chronic and rare skin disorders.View Forte Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings Intuitive Surgical (10/21/2025)Nasdaq (10/21/2025)Netflix (10/21/2025)Texas Instruments (10/21/2025)Citigroup (10/21/2025)Chubb (10/21/2025)Capital One Financial (10/21/2025)Danaher (10/21/2025)Elevance Health (10/21/2025)GE Aerospace (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
